Search clinical trials for: Targeted B7-H3 UCAR-T cell injection

Total 836 results

Shanghai Tongji Hospital, Tongji University School...
Shanghai AbelZeta Ltd.

Completed

A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy

B Cell Lymphoma

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
University of Florida
United States Department of Defense; AM Rosen Foundation

Recruiting

Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (IMPACT) (IMPACT)

Glioblastoma | Glioblastoma Multiforme

United States
Beijing Immunochina Medical Science & Technology...
Peking University People's Hospital

Not yet recruiting

INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia

Leukemia, B-cell
Weijia Fang, MD
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Renal Cell Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Metastatic Tumor

China
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Renal Cell Carcinoma | Ovarian Cancer | Cervix Cancer | Advanced Solid Tumor | Metastatic Tumor

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer

Renal Cell Carcinoma | Advanced Cancer | Metastatic Tumor

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors

Stomach Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Recurrent Cancer | Metastatic Tumor

China
Weijia Fang, MD
Chongqing Precision Biotech Co., Ltd

Recruiting

A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

Stomach Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Recurrent Cancer | Metastatic Tumor

China
PeproMene Bio, Inc.
City of Hope Medical Center

Recruiting

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

United States
CARsgen Therapeutics Co., Ltd.
RenJi Hospital; First Affiliated Hospital of Zhejiang University

Completed

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-cell Non-Hodgkin Lymphoma

China
First Affiliated Hospital of Zhejiang University

Unknown

An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Diffuse Large B Cell Lymphoma

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
Baylor College of Medicine
National Cancer Institute (NCI); The Methodist Hospital Research Institute; Center...

Active, not recruiting

Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (TACTAL)

Hodgkin Disease | Hodgkin Lymphoma | Non-Hodgkin Lymphoma

United States
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

LILRB4 STAR-T Cell Therapy for Monocytic Leukemia

Chronic Myelomonocytic Leukemia | Acute Myelogenous Leukemia

China
Shanghai Changzheng Hospital

Recruiting

Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease

Systemic Sclerosis | Sjogren's Syndrome | Antiphospholipid Syndrome | ANCA Associated Vasculitis | Systemic Lupus Erythematosus (SLE) | Inflammatory Myopathy

China
Chimeric Therapeutics

Recruiting

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Gastric Cancer | Colorectal Cancer | Neuroendocrine Tumors

United States
Ruijin Hospital
UTC Therapeutics Inc.

Recruiting

Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors (Amaretto)

Refractory Malignant Solid Neoplasm

China
China Meitan General Hospital
Marino Biotechnology Co., Ltd.

Unknown

Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors

Mesothelin Positive Tumors

China
CARsgen Therapeutics Co., Ltd.
Fudan University; Peking University Cancer Hospital & Institute

Recruiting

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Pancreatic Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

Liver Carcinoma | Hepatic Cell Carcinoma

China
Chinese PLA General Hospital
UTC Therapeutics Inc.

Recruiting

CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors

Solid Tumor, Adult

China
Chinese PLA General Hospital
UTC Therapeutics Inc.

Recruiting

CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma

Lymphoma

China
Wuhan Union Hospital, China
Shanghai Cell Therapy Group Co.,Ltd

Unknown

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Non-small-cell Lung Cancer | Mesothelioma

China
Chinese PLA General Hospital

Unknown

Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors

Solid Tumor, Adult

China
Essen Biotech

Recruiting

Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases (BAH247)

Autoimmune Diseases | Systemic Lupus Erythematosus | Sjogren's Syndrome | Systemic Lupus Erythematosus Acute

China
Sotio Biotech Inc.
SOTIO Biotech AG; SOTIO Biotech a.s.

Recruiting

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (DUET-1)

Hepatocellular Carcinoma | Squamous Cell Carcinoma of the Lung | Merkel Cell Carcinoma | Myxoid/Round Cell Liposarcoma

United States
Peking Union Medical College Hospital
Beijing Immunochina Medical Science & Technology Co., Ltd.

Unknown

Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma

Multiple Myeloma

China
Shanghai Cell Therapy Group Co.,Ltd
Shanghai 10th People's Hospital

Unknown

αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors

Colorectal Cancer | Ovarian Cancer

China
Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd.

Unknown

BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Myeloma

China
Roger Williams Medical Center
Sirtex Medical

Completed

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases (HITM-SIR)

Liver Metastases

United States
Lazaros Lekakis
Genentech, Inc.

Recruiting

CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | Aggressive Non-Hodgkin Lymphoma

United States
Zhejiang University
CARsgen Therapeutics Co., Ltd.

Completed

4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3

Advanced Hepatocellular Carcinoma

China
Xinqiao Hospital of Chongqing
The First Affiliated Hospital of Anhui Medical University; Chongqing University... and other collaborators

Unknown

Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

B Cell Leukemia | Relapsed Adult ALL

China
Wenbin Qian
Zhejiang Provincial Tongde Hospital

Unknown

Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.

B Cell Lymphoma

China
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Chinese PLA General Hospital
Peking University; EdiGene Inc.

Recruiting

TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

Non Hodgkin's Lymphoma

China
CARsgen Therapeutics Co., Ltd.

Unknown

Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma

Lung Squamous Cell Carcinoma

China
Chinese PLA General Hospital

Recruiting

TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Non-hodgkin Lymphoma

China
Chinese PLA General Hospital

Recruiting

TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL

Non-hodgkin Lymphoma,B Cell

China
Xinqiao Hospital of Chongqing
Chongqing University Cancer Hospital; 920th Hospital of Joint Logistics Support... and other collaborators

Not yet recruiting

Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL

Lymphoma, Non-Hodgkin

China
Seattle Children's Hospital

Active, not recruiting

A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia

B Cell Leukemia

United States
Shanghai Cell Therapy Group Co.,Ltd

Active, not recruiting

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

Non-Hodgkin Lymphoma, B-cell

China
Eden BioCell Ltd.
National Taiwan University Hospital

Terminated

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

Taiwan
Hebei Yanda Ludaopei Hospital
China Immunotech (Beijing) Biotechnology Co., Ltd.

Completed

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

B-cell Lymphoma

China
Beijing Tsinghua Chang Gung Hospital
China Immunotech Pharmaceuticals Co.Ltd.

Suspended

CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.

B-cell Non-Hodgkin's Lymphoma

China
Autolus Limited

Completed

CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA)

Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | B-cell Acute Lymphoblastic Leukemia | Refractory Childhood Acute Lymphoblastic Leukemia

United Kingdom
Henan Cancer Hospital
Henan Hualong Biotechnology Company

Unknown

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Refractory | B-Cell Lymphoma Stage I | Relapsed

China
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Insel Gruppe AG, University Hospital Bern

Not yet recruiting

PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) (PRONTO)

Lymphoma | Leukemia | Myeloma

Switzerland

Search clinical trials for: Targeted B7-H3 UCAR-T cell injection

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations